Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

ClinicalTrials.gov ID: NCT05879107

Public ClinicalTrials.gov record NCT05879107. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Open-label, Randomized, Controlled, Multi-Country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co Administered With PCV20 in Adults Aged 60\xa0Years and Older

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.

Study identification

NCT ID
NCT05879107
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,113 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 25, 2023
Primary completion
Dec 5, 2023
Completion
May 6, 2024
Last update posted
May 17, 2025

2023 – 2024

United States locations

U.S. sites
20
U.S. states
12
U.S. cities
20
Facility City State ZIP Site status
GSK Investigational Site Guntersville Alabama 35976
GSK Investigational Site Phoenix Arizona 85023
GSK Investigational Site Huntington Beach California 92647
GSK Investigational Site Modesto California 95350
GSK Investigational Site Hamden Connecticut 06517
GSK Investigational Site Clearwater Florida 33756
GSK Investigational Site DeLand Florida 32720
GSK Investigational Site Jupiter Florida 33458
GSK Investigational Site Largo Florida 33777
GSK Investigational Site Orlando Florida 32801
GSK Investigational Site West Des Moines Iowa 50266
GSK Investigational Site New Orleans Louisiana 70115
GSK Investigational Site Troy Michigan 48085
GSK Investigational Site St Louis Missouri 63110
GSK Investigational Site Cincinnati Ohio 45212
GSK Investigational Site North Charleston South Carolina 29405
GSK Investigational Site Dallas Texas 75251
GSK Investigational Site Frisco Texas 75033
GSK Investigational Site Mesquite Texas 75149
GSK Investigational Site Plano Texas 75024

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05879107, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 17, 2025 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05879107 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →